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ABSTRACT
Introduction: The objective of this study was to
investigate the frequency of lipohypertrophy
(LH) and the associated risk factors in young
patients with type 1 diabetes mellitus (T1DM).
Methods: This cross-sectional study was
conducted on a sample of 174 patients with
T1DM (aged 13–18 years) treated with multiple
daily insulin injections for a minimum duration
of 1 year. The study was performed at the
Diabetes Treatment Center, Prince Sultan
Military Medical City (Riyadh, Saudi Arabia),
between July 2015 and September 2015.
Information regarding patients’ age, weight,
height, adjusted body mass index (BMI),
period of the diabetic condition, length of
needle used, number of injections per day,
injection locations, insulin regimen, and
glycosylated hemoglobin (HbA1c) were
recorded. LH was assessed using the palpation
technique.
Results: Nearly 46% of patients were found to
reuse needles, while 42.5% failed to alternate the
injection site and 23% revealed unexplained
hypoglycemic events. A substantial percentage of
patients (approximately 47%) showed grade 1 LH,
followed by 33.7% with grade 2 and 19.3% with
grade 3 LH. A higher frequency of LH was observed
in the thigh region (n= 28, 33.7%) than in the
arm, which was second highest (n= 23, 27.7%).
Patients aged C16 years showed a higher
frequency of LH than those aged\16 years.
Patients with uncontrolled diabetes mellitus had
a greater likelihood of having LH (59.5%) than
those with controlled diabetes (20.8%). Significant
differences in LH were observed based on needle
length, needle reuse, and rotation of the injection
sites. On performing regression analysis, the
independent risk factors for LH were found to be
as follows: higher BMI, higher HbA1c, a higher
number of injection sites, a higher rate of needle
reuse and failed to alternate the injection site.
Conclusion: As the frequency of LH was found
to be high in Saudi patients with T1DM, it is
essential to educate patients on the risk factors
for LH and on diabetic control.
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INTRODUCTION
In Saudi Arabia, type 1 diabetes mellitus (T1DM)
has been identified as among the most common
endocrine metabolic disorders in children and
adolescents, and is accompanied by serious
acute and chronic complications [1, 2]. Over
the past 3 eras, the incidence T1DM has been
rising in Saudi Arabia and the prevalence of
T1DM in Saudi Arabian children and
adolescents is currently 109.5 per 100,000
people [1, 2]. T1DM is chiefly characterized by
the inability of the pancreas to produce insulin
resulting from the autoimmune destruction of
the beta cells [3]. Patients need exogenous
insulin throughout their lifetime to survive,
either via multiple injections every day or via
continuous subcutaneous insulin infusion if
required [3–5]. For the majority of patients,
two or more daily insulin injections are
mandatory, with dose adjustments based on
blood glucose levels. Injections or an insulin
pump can be used to administer insulin [3–5].
Diabetes management involves patients
injecting themselves. As this ranks among the
chief requirements [6, 7], patients must learn
the correct injection technique to avoid
intramuscular injections and appropriately
deliver the insulin into the subcutaneous
tissues, as well as to prevent common
complications like lipohypertrophy (LH)
[8–10]. LH is the most prevalent and
recognized local cutaneous complication of
insulin therapy [10, 11]. The significance of
this complication is not only cosmetic as it may
also influence insulin absorption. However, its
effect on glycemic control remains unclear [12].
Several factors are reported to affect the
development of LH, such as: the period of
insulin usage, gender, body mass index (BMI),
injection site, recurrent tissue trauma from
failure to rotate injection sites, and the
frequency of needle reuse [8, 10, 13]. Although
there are important implications of LH for
diabetes, very limited information and research
are available on LH, particularly in the young
Saudi population [2, 14]. Therefore, in this study
we determined to investigate the frequency of
LH and the associated risk factors in the young
populace with T1DM in Saudi Arabia.
METHODS
Study Design and Setting
This cross-sectional study was performed on a
sample of 174 patients with T1DM (aged
13–18 years). Patients had undergone
treatment with multiple daily insulin (MDI)
injections for over 1 year at the Diabetes
Treatment Center, Prince Sultan Military
Medical City (PSMMC, Riyadh, Saudi Arabia),
from July 2015 to September 2015. This study
was conducted in accordance with the
Declaration of Helsinki, and approval for the
study protocol was granted by the research
ethics committee of the PSMMC. Patients were
informed about the aim and methods of the
study verbally and in written form. Written
consent was received from patients before the
completion of study.
Patient Selection Criteria
All the participants were deliberately and
conveniently selected based on their
availability during their routine outpatient
clinic visits. Information regarding the study,
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its objectives, and the methodology involved
was given to the parents and the adolescents,
both verbally and in writing. The participants
could opt out of the research at any time and no
explanations were required.
Inclusion and Exclusion Criteria
All patients aged 13–18 years old, who were
treated with MDI injections, with T1DM, who
were followed up for a minimum of 1 year, and
having no other concomitant chronic disease
were included in the study. Those excluded
were patients treated with insulin pump
therapy, as well as those with a history of
psychopathology, medical instability, or visual,
hearing, or cognitive impairment.
Data Collection
The patients’ age, weight, height, adjusted BMI,
period of diabetes, needle length, number of
injections per day, injection sites, and insulin
regimen were recorded.
Body Mass Index
BMI was computed by dividing the weight in
kilograms by the square of height in meters (kg/
m2) and BMI z score was also calculated
(adjusted for child age and gender). The
z score (or SD score) was calculated as per the
formula (Xi-Mx)/SD, where Xi is the actual
measurement, Mx is the mean value for that age
and gender, and SD is the standard deviation
corresponding to that age and gender [15].
Hypoglycemia and Frequent Unexplained
Hypoglycemia
Hypoglycemia was defined as the occurrence of
one or more symptoms of hypoglycemia (such as
palpitations, tiredness, sweating, strong hunger,
dizziness, and tremor) and a confirmed blood
glucose level of B60 mg/dL (3.3 mM/L) [8].
Frequent unexplained hypoglycemia was
defined as having a hypoglycemic episode one
or more times a week in the absence of a definable
precipitating event, such as a change in
medication, diet, or activity [8].
Glycosylated Hemoglobin
Information on the participants’ most recent
insulin dose and glycosylated hemoglobin
(HbA1c) values for the blood glucose control
were retrieved from their medical records for
the research. The HbA1c test is the most reliable
form of diabetes diagnostic assessment,
providing a good indication of glycemic
control. A HbA1c value \7% is normally
accepted as a good level of control [16].
Lipohypertrophy
A trained diabetes educator, skilled in
performing observation and palpation
techniques, assisted in the evaluation of LH in
patients. LH values were distinguished as
follows: grade 0 = no change; grade 1 = visible
hypertrophy of fat tissue but with normal
consistency on palpation; grade 2 = intensive
fat tissue thickening but with firm consistency;
and grade 3 = lipoatrophy [17]. Participants and
their caretakers involved in the study were
interrogated regarding the methods of
administering the insulin and site rotation. All
the participants were treated with MDI
injections using insulin aspart and insulin
glargine therapy. Training was given on
routine care; patients were taught to rotate the
injection sites daily based on a special scheme:
left, right arm/left, right thigh and/or
abdominal area.
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Statistical Analysis
Microsoft Excel 2010 (Microsoft Corporation,
Seattle, WA, USA) and SPSS version 20 (SPSS
Inc., Chicago, IL, USA) were used to analyze
data. Besides the descriptive analysis,
Chi-square test was used to find out the
associations between LH and selected factors
for statistical significance. Logistic regression
was used to determining the role of influencing
factors in development of LH. A P value of
\0.05 was considered statistically significant.
RESULTS
Participant Characteristics
Demographic and clinical variables of the study
population are presented in Table 1. The study
population had a mean (±SD) age of
15.43 ± 1.97 years, and included 90 males
(51.7%) and 84 females (48.3%). The mean
(±SD) duration of T1DM diagnosis was
6.1 ± 4.5 years. A total of 121 (69.5%) patients
were identified with uncontrolled diabetes
(HbA1c[7%). Nearly 46% of the patients were
found to reuse their needles, while 42.5% failed
to rotate the injection sites and 23% of patients
had unexplained hypoglycemic events. Most
patients were revealed to have grade 1 LH
(47%); the rest had grade 2 (33.7%) and grade
3 (19.3%; Fig. 1). Higher frequency of LH was
observed in the thigh area (n = 28, 33.7%)
followed by the arm (n = 23, 27.7%).
The frequency of LH based on the different
study variables is presented in Table 2. Patients
aged C16 years had a higher frequency of LH
than those aged\16 years. Patients with
uncontrolled diabetes had a greater possibility
of LH (59.5%) compared with those with
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diabetes under control (20.8%). Significant
differences were observed in the LH depending
on BMI, education, duration of DM, needle
length, dose of insulin, needle reuse, injection
site rotation, and unexplained hypoglycemic
events (P\0.05).
All variables that were statistically significant
in Chi-square test were added for regression
analysis. Regression analysis showed that
variables such as higher BMI, higher HbA1c, a
higher number of injection sites, higher needle
reuse and failed to alternate the injection site
were independent risk factors for LH. Variables
such as gender, age, education level, duration of
T1DM, needle length, dose of insulin, and
unexplained hypoglycemic events were not
independently significant and their influence
on LH is likely dependent on other factors
(P[0.05; Table 3).
DISCUSSION
The frequency of and factors influencing LH
among the young individuals with T1DM were
investigated. LH has been identified in several
studies as the most common cutaneous
complication resulting from insulin therapy,
occurring in almost 50% of patients with T1DM
[18, 19]. In this study, LH was reported in 47.7%
of the insulin-treated patients with T1DM (with
47% showing grade 1 LH, 33.7% with grade 2,
and 19.3% with grade 3).
One study has recently reported a strong
relationship between the occurrence of LH and
the non-rotation of injection sites;
implementing the correct rotation technique
had the strongest protective value against LH
[8]. It is also supported by the fact that only 5%
of the patients who correctly rotated injection
sites had LH, whereas 98% of the patients with
LH either did not rotate the sites or did so
incorrectly [8]. In another study, the prevalence
of the LH was observed to be higher in patients
who neither changed their injection site nor
remembered to do so [18]. However, one study
reported contradictory findings in which the
frequency of LH was not significantly
influenced by injection site rotation and stated
that several young patients without LH were
observed not rotating the injections sites
despite repeated instruction [14]. The current
study showed that 42.5% of the study
population failed to rotate their injection site.
On regression analysis, our study identified
Fig. 1 Frequency of lipohypertrophy at the different injection sites
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Male 47 (52.2) 43 (47.8) 0.207
Female 44 (52.4) 40 (47.6)
Age, years
\16 75 (68.8) 34 (31.2) \0.05
C16 16 (24.6) 49 (75.4)
Body mass index, kg/m2
B25 79 (65.3) 42 (34.7) \0.05
[25 12 (22.6) 41 (77.4)
Education
Primary 46 (80.7) 11 (19.3) \0.05
Secondary 45 (38.5) 72 (61.5)
Duration of diabetes, years
B5 68 (64.2) 38 (35.8) 0.001
[5 23(33.8) 45 (66.2)
Glycosylated hemoglobin, %
B7 42 (79.2) 11 (20.8) \0.05
[7 49 (40.5) 72 (59.5)
Needle length, mm
4 48 (76.2) 15 (23.8) \0.05
6 36 (94.7) 2 (5.3)
8 7 (9.6) 66 (90.4)
Dose of insulin, units per kg
B0.7 24 (80) 6 (20) \0.05
[0.7 67 (46.5) 77 (53.5)
Needle reuse
Yes 23 (28.8) 57 (71.2) \0.05
No 68 (72.3) 26 (27.7)
Rotation
Yes 77 (77) 23 (23) \0.05
No 14 (18.9) 60 (81.1)
Unexplained hypoglycemic events
Yes 12 (30) 28 (70) \0.05
No 79 (59) 55 (41)
Chi-square test, P\0.05 considered as signiﬁcant
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injection site rotation to be an independent risk
factor for LH. Repeated insulin administration
injected into a site caused the hypertrophic
lipid cells to replace the mid-dermal collagen.
Pain sensation was reduced in the LH areas [13].
This is one reason for patients to opt for
injections at that site, causing increased
dystrophy in the region [13, 20, 21]. It is quite
natural that, when the patient feels pain
injecting at a site other than the LH area, he
or she prefers to inject into the same site,
despite knowing the importance of rotating
sites [13, 21]. The majority of the patients in the
current study preferred to use the thigh for their
insulin injections. LH was reported to
frequently occur on both sides of the
umbilicus or in the mid-thigh regions, as these
are the most convenient and naturally
accessible locations for injections. Over time,
the area becomes hyposensitive [22].
Needle reuse when injecting insulin is quite
common among patients with T1DM [8].
However, as the needle can get deformed with
repeated use, it can either raise injection
morbidity or, more likely, render the patient
susceptible to LH or induce bleeding at the
injection site. The literature contains evidence
that the frequent reuse of insulin needles raises
the risk of infection [10, 23]. A European
epidemiological study on insulin injection
techniques indicated that patients who reused
needles carried 31% higher risk of LH than
those who avoided it. The current study showed
that 46% of participants reused the needles, and
that LH was 8% higher in the patients reusing
needles than in those who used fresh ones.
Regression analysis highlighted a strong
relationship between multiple reuse of a single
needle and LH in this study group.
In a recent study, LH was reported to occur less
frequently in patients were obese and overweight
versus those who were normal or underweight
[14]. Another study recorded a higher BMI to be
an independent risk factor for the occurrence of
LH [14]. The present study indicated that LH was
mainly linked to BMI. Regression analysis
performed revealed that LH was an independent
risk factor for the HbA1c level in the population
under study. Several studies have shown that
insulin repeatedly injected into the same site can
induce fat and scar tissue accumulation [8, 24].
This results in hard, fatty, and unattractive bumps
under the skin in the abdomen or thighs. More
significantly, these can interfere with patients’
insulin therapy. The tissue masses may impede
the insulin absorption, inducing a blood glucose
spike, even producing dangerously low glucose
levels later. While LH on its own is not
life-threatening, it can make the diabetes harder
to manage [18].
Table 3 Signiﬁcant results of logistic regression
Variables Adjusted odds ratio P value
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As this study has a significant limitation,
having been conducted in a single medical
center, more research is warranted.
Nevertheless, this study offers important
insights into LH, regarding both its frequency
and causes, among adolescents with T1DM in
Saudi Arabia.
CONCLUSIONS
In summary, the frequency of LH is clearly high
among adolescents with T1DM in Saudi Arabia,
emphasizing the importance of educating
patients on the risks of LH, the need to
correctly rotate the injection sites and to avoid
reuse of needles, and on diabetes control. It is
also crucial that all patients with diabetes be
educated in order to circumvent developing LH,
with re-education being mandatory for those
with this condition.
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